These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31323125)

  • 21. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
    J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of tolvaptan on ascites due to malignancy].
    Mitsuhashi N; Nemoto S; Satoh Y; Aoki Y; Teranaka R; Sasaki K; Shimazaki R; Ueda A; Nishino H; Akiyama T; Hosokawa I; Yoichi T; Kawamoto J; Kuboki S; Yoshitomi H; Kato A; Shimizu Y; Ohtsuka M; Shimizu H; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):201-5. PubMed ID: 25743139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cases with Refractory Ascites and a Delayed Response to Tolvaptan.
    Hagiwara S; Nishida N; Chishina H; Ida H; Sakurai T; Komeda Y; Kitano M; Kudo M
    Intern Med; 2016; 55(22):3273-3277. PubMed ID: 27853068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.
    Yan L; Xie F; Lu J; Ni Q; Shi C; Tang C; Yang J
    BMC Gastroenterol; 2015 Jun; 15():65. PubMed ID: 26054761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Tokushige K
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):87. PubMed ID: 30563565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study.
    Kudo T; Murai Y; Kojima Y; Uehara K; Satoh T
    Jpn J Clin Oncol; 2021 Mar; 51(3):354-362. PubMed ID: 33173939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I
    Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure].
    Shinoda R; Shinoda Y; Mori T; Yoshimura T
    Yakugaku Zasshi; 2021; 141(2):281-288. PubMed ID: 33518649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    Hiramine Y; Uto H; Mawatari S; Kanmura S; Imamura Y; Hiwaki T; Saishoji A; Oku M; Tokushige K; Maenohara S; Ido A
    J Gastroenterol; 2021 Jan; 56(1):54-66. PubMed ID: 32959093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.
    Huang WL; Yang Y; Yang J; Yang J; Wang HB; Xiong XL; Zhang YF
    Herz; 2018 Jun; 43(4):338-345. PubMed ID: 28523370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood Urea Nitrogen/Creatinine Ratio and Response to Tolvaptan in Patients with Decompensated Heart Failure: A Retrospective Analysis.
    Okayama D; Suzuki T; Shiga T; Minami Y; Tsuruoka S; Hagiwara N
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):289-93. PubMed ID: 25940650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.
    Chai L; Li Z; Wang T; Wang R; Pinyopornpanish K; Cheng G; Qi X
    Expert Rev Gastroenterol Hepatol; 2023; 17(10):1041-1051. PubMed ID: 37794713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
    Kawaratani H; Fukui H; Moriya K; Noguchi R; Namisaki T; Uejima M; Kitade M; Takeda K; Okura Y; Kaji K; Nishimura N; Takaya H; Aihara Y; Sawada Y; Sato S; Seki K; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2017 Aug; 47(9):854-861. PubMed ID: 27704665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.
    Tahara T; Mori K; Mochizuki M; Ishiyama R; Noda M; Hoshi H; Lefor AK; Shinozaki S
    Biomed Rep; 2017 Dec; 7(6):558-562. PubMed ID: 29250327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
    Tang J; Wang Y; Han T; Mao Q; Cheng J; Ding H; Shang J; Zhang Q; Niu J; Ji F; Chen C; Jia J; Jiang X; Lv N; Gao Y; Wang Z; Wei Z; Chen Y; Zeng M; Mao Y
    BMC Gastroenterol; 2020 Nov; 20(1):391. PubMed ID: 33213378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.